Начало › Рак на белия дроб с недребноклетъчен тип › Мисисипи
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Мисисипи
20 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в Мисисипи.
Градове в Мисисипи
Официален текст на проучването (английски)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Hattiesburg Clinic /ID# 248033, Hattiesburg
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 5.10.2026 г. · NCT04928846Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- University of Mississippi Medical Center, Jackson
- и още 3
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 5.10.2026 г. · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven
Набиране на участнициФаза 2
Възраст 18 и повече · Всички полове · Обновено на 2.10.2026 г. · NCT07293247A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Local Institution - 0180, Hattiesburg
Набиране на участнициФаза 2
Възраст 18 и повече · Всички полове · Обновено на 2.10.2026 г. · NCT07680764Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- University of Mississippi Medical Center, Jackson
- и още 3
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 1.10.2026 г. · NCT06498635A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Baptist Cancer Center, Southaven
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 28.09.2026 г. · NCT07144280Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Hattiesburg Clinic Hematology/Oncology ( Site 0104), Hattiesburg
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 25.09.2026 г. · NCT06170788Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Hattiesburg Clinic Hematology/Oncology, Hattiesburg
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 25.09.2026 г. · NCT07222566This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Jackson Oncology Associates, PLLC, Jackson
- Jackson Oncology Associates, PLLC, Jackson
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 25.09.2026 г. · NCT06758401Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Hattiesburg
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 23.09.2026 г. · NCT06357533A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Hattiesburg Clinic Hematology/Oncology, Hattiesburg
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 23.09.2026 г. · NCT06561386Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Hattiesburg
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 18.09.2026 г. · NCT06767514Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Jackson Oncology Associates - The Hederman Cancer Center, Jackson
Набиране на участнициФаза 2/3
Възраст 18 и повече · Всички полове · Обновено на 16.09.2026 г. · NCT04613596A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- North Mississippi Hematology and Oncology Associates, Tupelo
Набиране на участнициФаза 3
Възраст 18 и повече · Всички полове · Обновено на 8.09.2026 г. · NCT06119581Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- University of Mississippi Medical Center, Jackson
- и още 3
Набиране на участнициФаза 2
Възраст 18 и повече · Всички полове · Обновено на 3.06.2026 г. · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- Baptist Memorial Hospital and Cancer Center-Union County, New Albany
- и още 2
Набиране на участнициФаза 2
Възраст 18 и повече · Всички полове · Обновено на 6.05.2026 г. · NCT06116682Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- Gulfport Memorial Hospital, Gulfport
- и още 3
Набиране на участнициФаза 2/3
Възраст 18 и повече · Всички полове · Обновено на 5.05.2026 г. · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- Baptist Memorial Hospital and Cancer Center-Union County, New Albany
- и още 2
Набиране на участнициФаза 2
18 Minutes · Всички полове · Обновено на 5.05.2026 г. · NCT06031688Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- Baptist Memorial Hospital and Cancer Center-Union County, New Albany
- и още 2
Набиране на участнициНаблюдателно проучване
Възраст 18 и повече · Всички полове · Обновено на 17.03.2026 г. · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Hattiesburg
Набиране на участнициНаблюдателно проучване
Всички възрасти · Всички полове · Обновено на 28.10.2025 г. · NCT03452774От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.